The Evidence Layer Behind Faster Pharma R&D

Recent pharmaceutical recruitment in India offers a useful view into how global R&D work is changing. In Hyderabad, Novartis sought a clinical pharmacology leader for First-in-Human and clinical pharmacology studies. Amgen advertised a mathematical modeling lead whose remit includes PK/PD modeling, dataset curation, visualization and workflow automation. In Bengaluru, a publicly indexed Novo Nordisk listing described patent coordination work supporting global intellectual property operations. [1][2][3]

These roles sit in different functions, but they point to the same management problem. Drug-development decisions increasingly depend on whether scientific evidence can move reliably between discovery, Data Management, Data Analytics, Artificial Intelligence, clinical pharmacology, regulatory teams and IP operations. For R&D leaders, the quality of that evidence layer affects investment choices, study design, regulatory planning, patentability assessments, Technology Transfer and eventual commercialization.

Evidence readiness now controls development speed

Model-informed drug development is moving closer to the centre of regulatory decision-making. The final ICH M15 guidance, published by the US FDA in June 2026, sets out expectations for planning, evaluating, documenting and communicating evidence derived from models. FDA guidance also states that population pharmacokinetic analysis is used to guide drug development, support tailored dosing and, in some cases, reduce the need for post-marketing requirements or commitments. [4][5]

This raises the standard for the underlying data. A model may be mathematically sound and still provide weak decision support when source studies are difficult to compare, population attributes are incomplete, units are inconsistent or analytical methods are poorly documented.

A pharmacometric model is like a flight simulator. Sophisticated software cannot compensate for inaccurate aircraft parameters, incomplete maps or poorly defined operating conditions.

The operational signals can be read as follows:

A verified case in model-ready data

Amgen’s April 13, 2026 posting provides a direct example. The role was placed within clinical pharmacology, modeling and simulation and called for computational strategies supporting pharmacometric analysis. Its responsibilities included curating and visualizing complex datasets, developing PK/PD and quantitative systems pharmacology methods, automating workflows and integrating pharmacokinetics, pharmacodynamics, patient characteristics and disease biology for dose and study-design decisions. [2]

This is more than a modeling requirement. It is a Data Management requirement. Study-level metadata, demographic variables, dose schedules, formulations, routes of administration and analytical methods must be standardized before they can be compared or reused. Data Visualization then becomes part of scientific review rather than a presentation task performed after analysis.

FDA’s pharmacometric submission guidance reflects the same need for reproducibility. It addresses dataset formats, variable definitions, scripts, software dependencies, execution order, model code, diagnostic plots and the clinical application of results. [6]

The contrarian point: more AI talent will not repair weak evidence

Pharma companies are recruiting AI, data science and scientific software expertise. Novartis, for example, listed a Senior Expert Data Science & AI position in Hyderabad in June 2026, alongside wider research roles involving PK Sciences, scientific software and data42. [7]

The defensible contrarian view is that algorithm selection is rarely the first constraint. Novartis’s own account of data42 described the work required before advanced analysis becomes useful: cleaning isolated and unstructured data, moving it into a machine-readable environment and defining precise scientific questions. [8]

AI can accelerate extraction, classification, comparison and prediction. It cannot determine whether an undocumented dose conversion is scientifically defensible or whether two study populations are comparable without sufficient context. Data Curation, indexing, provenance controls and expert review remain part of the scientific method.

Patent work should begin before the invention package is complete

The patent signal from Bengaluru matters because IP operations are often treated as a downstream administrative function. That sequence creates avoidable risk.

Prior art search should begin while research questions and claim boundaries can still be adjusted. Patentability review can inform experimental design and identify where comparative data may strengthen an inventive-step argument. Freedom-to-operate work should examine relevant granted and pending claims in the markets where a product, process or platform may be commercialized.

WIPO notes that an FTO analysis begins with patent searching and legal assessment of possible infringement. It also stresses that holding a patent does not itself establish freedom to commercialize, because broader third-party rights may still apply. [9]

For Technology Transfer and commercialization teams, this means patent landscapes, invention disclosures, regulatory evidence, licensing assumptions and development data should be reviewed together. Patent drafting and filing support is stronger when claims can be traced to laboratory records, curated scientific evidence and the intended commercial use.

How Saturo Global supports the evidence workflow

Saturo Global supports research, data and IP teams working across these connected requirements. The Human PK Database provides structured human pharmacokinetic information, including PK attributes and study context such as population, dose, formulation, administration route and analytical method. These fields can support benchmarking, trial planning and PK/PD analysis, subject to programme-specific scientific review. [10]

Saturo Global’s wider capabilities include Data Curation & Management, Indexing & Abstracting, Strategic Patent Support and Data Visualization. Support areas include prior art search, freedom-to-operate support, patent landscape support, patent drafting and filing support, and IP protection strategy. PatBase, Origin and Chemical Explorer can be incorporated into structured patent-intelligence workflows for reviewing patent families, technical concepts, chemical information and competitive activity. [11][12]

The management objective is straightforward: maintain evidence that can be found, checked, analysed and transferred without rebuilding its meaning at every handoff.

Schedule a demo for a walkthrough of Minesoft PatBase and Origin.

References

[1] Novartis. 2026. “Associate Director, Translational Medicine Expert, TM Clinical Pharmacology.” Novartis Careers.

[2] Amgen. 2026. “Principal Scientist – Mathematical Modeling Lead/Pharmacometric Modeling and Simulation.” Amgen Careers.

[3] BiotechReality JobFinder. 2026. “Patent Coordinator – Novo Nordisk.” BiotechReality.

[4] US Food and Drug Administration. 2026. “M15 General Principles for Model-Informed Drug Development.” FDA.

[5] US Food and Drug Administration. 2022. “Population Pharmacokinetics.” FDA.

[6] US Food and Drug Administration. 2021. “Model | Data Format.” FDA.

[7] Novartis. 2026. “Biomedical Research Career Search.” Novartis Careers.

[8] Mijuk, Goran. 2020. “Meet Achim, Leading the data42 Program.” Novartis.

[9] World Intellectual Property Organization. “Launching a New Product: Freedom to Operate.” WIPO Magazine.

[10] Saturo Global. “Human PK Database.” Saturo Global.

[11] Saturo Global. 2025. “Services.” Saturo Global.

[12] Saturo Global Research Services Team. 2026. “When Data Earns the Right to Steer Decisions.” Saturo Global.